LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)

Authors:
  • XLX. Le
    X. Le
  • JPJ. Patel
    J. Patel
  • ESE. Shum
    E. Shum
  • RSR.E. Sanborn
    R.E. Sanborn
  • CBC.S. Baik
    C.S. Baik
  • CSC.A. Shu
    C.A. Shu
  • CKC. Kim
    C. Kim
  • FIFidler
    Fidler
  • RHR. Hall
    R. Hall
  • NHN. Hanna
    N. Hanna
  • NMN. Mohindra
    N. Mohindra
  • JSJ.K. Sabari
    J.K. Sabari

Abstract
No abstract available